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                                                   Abstract 
Title  : Feasibility and oncological safety of axillary reverse mapping in early breast 
cancer, using premixed serum and  indocyanine green dye flourescence technique and 
an in-house near-infrared fluorescence imaging system and methylene blue dye. 
Department : Department of Endocrine Surgery and Bioengineering, Christian 
Medical College, Vellore – 632 004. 
Name of the candidate: Jyothsna M 
Degree and subject: MS General Surgery 
Name of the Guide:  M J Paul.  
Objectives : To determine the metastatic rate and compare the detection rates of arm 
lymphatics and arm nodes,  between  serum and indocyanine green (ICG) dye, using 
an in-house near infrared (NIR) fluorescent imaging system and methylene blue dye,  
in patients with early breast cancer. 
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Methods: This IRB approved study included 52 patients with early breast cancer, 
undergoing ALND, equally allocated into two groups. In one group standardized 
solution of serum and ICG was injected intradermally posterior to the proximal part of 
the arm inter-muscular groove and in-house NIR imaging system was used and 2ml of 
methylene blue was injected at the same site in the other group. The identified ARM 
node is sent for histo-pathological examination to detect metastasis. 
 
Results:  After identifying the accurate site of injection, the identification rate of arm 
lymphatics and arm lymph node using serum and ICG and methylene blue were 
comparable. Metastatic rate in the arm node was low (5.8%). Thus ARM technique is 
feasible and safe in patients with early breast cancer.  
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Introduction: 
Surgical management options for patients with breast cancer vary from modified 
radical mastectomy, which includes axillary dissection for clinically axillary node  
positive  patients to simple mastectomy with sentinel lymph node biopsy in 
cytologically assessed axillary node negative patients.  Axillary surgery is associated 
with  complications such paraesthesia over the arm and seroma formation; however 
lymphedema of the ipsilateral arm, remains as  the most troublesome sequel of 
axillary dissection in patients with breast cancer. 
Symptom relief can be obtained to a certain extent by both manual and pneumatic 
devices, graded compression garments, pressure bandages, which aid in lymphatic 
drainage of the affected limb.(1) 
Lymphedema predisposes the affected upper limb to repeated superficial soft tissue 
infections, leading to hospitalisation  and administration of antibiotics intravenously. 
It also causes discomfort and limits daily activities of the affected individuals.(2) 
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 Lymphatic system 
Anatomy and physiology: 
Human lymphatic system consists of three important components, first being an 
intricate and delicate network of capillaries which collect the extracellular fluid 
from different tissues and organs. Second, is a complex system of lymphatic 
channels and trunks which carry the lymph from the capillaries back in to the 
blood stream.  And thirdly, lymph nodes which filter the lymph as it passes 
through them. 
 
Lymph is formed by the interstial fluid in the extracellular spaces, which is 
absorbed into the lymphatic capillaries.  The diameter of lymphatic capillaries 
ranges from 10-50 microns and are lined by single layer endothelial cells, which 
lie on a basement membrane.  
 
       
1 
Endothelial cells overlap and these junctions function as valves and the allow the 
entry of small particles into the lymph. Collagen fibres prevent these capillaries from 
collapsing, by anchor them to the surrounding tissues. 
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Lymph is formed by diffusion and osmosis of extracellular fluid into the lymphatic 
capillaries. Inflow of lymph into the capillaries is regulated by osmotic gradient and 
by low luminal pressures caused by sequential contraction and forward propulsion of 
the lymph in the lymphatic channels.(3) 
Composition of lymph is the similar to that of the plasma, with albumin constituting 
the majority. It is colourless and contains leucocytes, lymphocytes and few red blood 
corpuscles. 
Lymphatic capillaries have many inter-capillary anastamoses which from plexuses 
and do not have valves. They form superficial and deep plexuses in the body. The 
superficial lymphatic plexus is smaller in calibre and communicate with deep plexuses 
at various places. 
Lymphatic channels are distributed widely in the almost all parts of the body except in 
epidermis, cartilage, bone marrow, central nervous system. These lymphatic channels 
drain into larger calibre lymphatic vessels, which in turn drain into lymphatic trunks, 
that communicate with the venous system. 
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The wall of the lymphatic vessels consists of three layers. 
1. Inner layer consists of thin, elongated, transparent endothelial cells which rest 
on the elastic basement membrane. 
2. Middle layer consists of circularly arranged smooth muscle fibres and elastin 
fibres. 
3. Outer layer consists of obliquely and longitudinally arranged smooth muscle 
and elastin fibres and connective tissue which attaches the lymphatic vessels to 
the adjacent tissues.(4) 
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Lymphatic flow in the tissues is determined by the rate of lymph formation, 
contraction of the circular and smooth muscle fibres in the wall of the lymphatic 
channels and forward propulsion of lymph and external pressures over the body, 
which can impede the lymphatic flow if they are prolonged at a one area. External 
pressure over the tissues can also enhance the lymphatic flow, when it is sequential 
and graded over a period of time. 
Lymphatic flow is unidirectional, due to the presence of valves in the lymphatic 
vessels, which give a beaded appearance to them. These valves comprise of fibrous 
tissue, lined by endothelial cells on either sides and are similar to the valves that are 
present in the veins and are more in number in the lymphatic system. Smooth muscle 
fibres contract 10-15 times a minute and propels the lymph forward at a speed of 4-5 
mm/sec. This peristalsis is regulated by filling pressure of 2-4 cm H20 and 
contraction, serotonin, prostaglandins and neural mechanisms. Lymphatic flow 
amounts to 2-4 L/day which varies according to physiological needs. 
 
Lymph nodes are oval shaped, small glands that are situated along the course of the 
lymphatic channels and when they are not enlarged are usually indistinguishable from 
surrounding adipose tissue. Lymph nodes are covered with a capsule, which gives rise 
to incomplete fibrous septa that divide the gland into open spaces.  
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These spaces are filled with lymphoid tissue containing lymphocytes and sinuses 
which form a communication between the afferent and efferent vessels entering and 
exiting the gland, respectively, at the hilum. 
Lymphatic system of the breast:  
Sappey, first described the lymphatic drainage of the breast in 1870. The breast 
lymphatic drainage is separate from the underlying pectoralis muscles and chest wall. 
It contains of a superficial lymphatic plexus which drain into the pectoral nodes, with 
a sub-areolar plexus which drains separately through the lymphatic channels into the 
pectoral or level I nodes in the axilla. 
Lymphatic capillaries are present in the dermis and these do not have valves. The 
lymphatic capillaries drain into pre-collecting vessels, which have valves. The pre-
collectors drain in the superficial lymphatic channels, which are present in the 
subcutaneous tissue.  Superficial lymphatic channels drain in to the lymph nodes in 
the axilla. The superficial lymphatic channels drain into the deep lymphatics channels 
present below the deep fascia covering the pectoralis major muscle. These lymphatic 
channels  drain into the axillary nodes. 
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Turner –warwick, in 1959 demonstrated that lymphatics of the breast drains separately 
into the axilla and not via sub-areolar plexus. There are perforating channels which 
connect the superficial and deep lymphatic channels. The deep lymphatic channels are 
present below the deep fascia. These perforating channels drain along the branches of 
internal mammary vessels and drain into the internal mammary nodes, which are 
situated along the internal mammary artery.(3)(5) 
Axillary lymph nodes are divided into 6 groups  
1. Anterior (pectoral) axillary nodes 
2. Posterior (sub scapular) axillary nodes 
3. Lateral (axillary vein) nodes 
4. Central nodes 
5. Apical nodes (sub clavicular) 
Interpectoral group (Rotter‟s lymph nodes) 
 
These lymph node groups are assigned to three levels according to their 
relationship with the pectoralis minor muscle. 
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Levels of axillary lymph nodes: 
Level 1:  includes lymph nodes which lie below the lower border of the pectoralis 
minor muscle 
Level 2: includes lymph nodes which lie behind the pectoralis minor muscle. 
Level 3: includes lymph nodes which lie above the upper border of pectoralis minor 
muscle and below the clavicle. 
 
Surgical anatomy of the axilla: 
Axilla is a pyramidal shaped space bound by four borders and has a base and an apex 
Borders of the axilla: 
Anterior border is formed by pectoralis major and minor muscles, along with 
subclavius muscle. 
Posterior border is formed by teres minor, latissimus dorsi, subscapularis muscles. 
Lateral border is formed by biccipital groove on the medial aspect of the humerus, on 
to which the anterior and posterior border muscles insert. 
Base is formed by skin, subcutaneous tissue and axillary fascia. 
Apex is formed by costo-clavicular ligament. 
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Medial border is formed by the ribs and the intercostal muscles along with the 
overlying serratus anterior muscle. 
Contents of axilla: 
Axillary pad of fat, which also contains the lymphatic channels and the axillary lymph 
nodes. 
Thoracodorsal vein and the artery, that course along the thoraco-dorsal nerve, along 
the posterior border. 
Long thoracic nerve, which courses along the medial border, over the serratus anterior 
muscle below the fascia and supplies the muscle. 
Medial and lateral pectoral nerves, which supply the pectoralis major and minor 
muscles. 
Intercosto-brachial nerves, which provide sensory supply to the arm and skin over the 
axilla. 
Axillary vein and the axillary artery, along with the brachial plexus also form the 
contents . 
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Axillary lymph node dissection: 
Surgical technique: 
Pre operative:  Informed consent has to be obtained prior to the procedure and side has 
to be marked correctly. All safety precautions for the patient have to be followed.  
Preoperative antibiotic should be administered thirty minutes prior to the procedure. 
Anaesthesia: The procedure is performed under general anaesthesia without giving 
neuromuscular agents to the patient, as it helps in identification of the motor nerves 
and prevent their injury during dissection. 
Preparation : The skin over the surgical field has to be prepared with alcohol/iodine 
based antiseptic solution.  This should extend from the neck, supraclavicular region to 
the ipsilateral inframammary region, in the longitudinal plane. Transversely, skin 
should be prepared from the opposite nipple upto the ipsilateral posterior axillary line. 
The ipsilateral arm should also be prepared circumferentially, up to the elbow and 
draped separately. 
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Incision:  
In patients undergoing axillary dissection, an incision along the skin crease, 2 cm 
below the axillary hair line, is made to gain access into the axilla. 
In patients who are undergoing modified radical mastectomy, axilla can be entered 
through the same incision after raising the skin flaps. 
Dissection:  Fatty tissue and lymph nodes below the axillary vein are cleared, taking 
care to avoid injury to axillary vein, thoracodorsal bundle and long thoracic nerve 
during dissection. Intercosto-brachial nerves can be identified and spared to prevent 
hyperasthesia over the medial aspect of the arm and skin over the axilla. Medial 
pectoral vessels are identified and preserved. Level III nodes can be cleared when 
there is a suspicion or when they are enlarged. Hemostasis should be achieved and 
drains have to placed under the flaps and in the axilla. Subcutaneous tissue closed 
with interrupted absorbable sutures and skin is closed with interrupted non-absorbable 
sutures. 
Post-operative complications: 
Hematoma :  Postoperative hematoma is known to occur in 2-10% of patients despite 
the advent of electrocautery.  Achieving good hemostasis is the key to prevent 
hematoma formation. 
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Seroma : Disruption of the lymphatic channels during dissection leads to lymph leak 
into the closed space, temporarily. This can be prevented by placing drains during the 
procedure and removing them once the output decreases. At times, seroma formation 
can occur after the drains are removed. In such situations, repeated aspiration can be 
done to evacuate the seroma, as it interferes with the wound healing. Patients also 
tolerate this procedure, due to the sensory loss over the flaps. 
Wound infection: Its reported incidence ranges from 1-20%. Staphylococcal 
organisms are the most common causative agents. Predisposing factors such as 
obesity, diabetes mellitus and elderly age are common. Use of preoperative 
cephalosporins, administered intravenously, reduces the wound infection rates by 
40%. (6) 
When there is a associated abscess or an underlying seroma, aspiration and drainage 
must be performed. Minimal wound discharge and surrounding cellulitis can be 
treated with oral antibiotics. When there is a persistent pus discharge and increased 
area of redness, hospital admission and administration of intravenous antibiotics 
should be considered.  
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Lymphedema of the ipsilateral arm  : it is one of the dreaded complication following 
axillary lymphnode dissection. Its incidence increases with the extent of axillary 
dissection. Most patients develop swelling of the ipsilateral arm with in 2 years and its 
incidence rises as duration from the time of surgery increases. 
Lymphedema occurs due to disruption of the lymphatic channels that drain the arm, 
during axillary dissection. As a result, the lymph in the arm lymphatic channel 
accumulates and extravasates into the surrounding tissue causing inflammatory 
reaction and fibrosis. This leads to non-pitting edema, and swelling of the affected 
arm.  Lymphedema causes significant morbidity in patients undergoing axillary 
dissection. And their day to day activities are limited due to pain, swelling and 
discomfort in the arm.  
Incidence of lymphedema ranges from 0-13%, even in patients undergoing Sentinel 
lymph node biopsy (SLNB), a procedure which helps to avoid axillary dissection, 
so as to prevent secondary lymphedema, in breast cancer patients with no enlarged 
axillary lymphnodes. (7)(8)  Lymphedema was found in 11-30% of patients 
undergoing ALND (9).  The highest reported incidence is 56% (10)  
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In a prospective study conducted on a cohort of 103 patients who were undergoing 
mastectomy with axillary lymph node dissection for proven breast cancer, in Christian 
Medical College, Vellore, the incidence of lymphedema was found to be 25.24%. 
Aims and Objectives 
 
The aim of this study is to assess the feasibility and oncological safety of axillary 
reverse mapping (ARM) in early breast cancer. 
The objectives of this study are  
1. To determine and to compare the detection rate and location of the arm 
lymphatics and lymph node using two different techniques, a premixed solution 
of autologous serum and indocyanine green(ICG) dye and an in-house near 
infra-red fluorescent  imaging  system, and  also by injecting 2 ml of methylene 
blue dye,  posterior to the medial groove of the ipsilateral arm. 
 
2. To determine the metastatic rate in the ARM node in breast cancer.  
The hypothesis is that the lymphatic pathway from the arm and the associated 
lymph node, may not be involved by metastasis from the primary breast cancer; 
therefore by preserving them secondary lymphedema may be prevented.  
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Literature review: 
 
 Axillary surgery is associated with  complications such paraesthesia over the arm and 
seroma formation; however lymphedema of the ipsilateral arm, remains  the most 
troublesome sequel following axillary dissection in breast cancer patients.   
Symptom relief can be obtained to a certain extent by both manual and pneumatic 
devices, graded compression garments, pressure bandages, which aid in lymphatic 
drainage of the affected limb.(1) 
Lymphedema predisposes the affected upper limb to repeated superficial soft tissue 
infections, leading to  hospital admissions and use of intravenous antibiotics. It also 
causes discomfort and limits daily activities of the affected individuals.(2) 
Incidence of lymphedema ranges from 0-13%, even in patients undergoing Sentinel 
lymph node biopsy (SLNB), a procedure which helps to avoid axillary dissection, 
so as to prevent secondary lymphedema, in breast cancer patients with no enlarged 
axillary lymphnodes. (7)(8) Lymphedema was reported in 11-30% of patients 
undergoing ALND (9).  The highest reported incidence is 56% (10)  
In a prospective study conducted on a cohort of 103 patients who were undergoing 
mastectomy with axillary lymph node dissection for proven breast cancer, in Christian 
Medical College, Vellore, the incidence of lymphedema was found to be 25.24%. 
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Axillary reverse mapping (ARM) is a technique first described in 2007, to prevent 
lymphedema in patients undergoing ALND. This technique was based on the 
evidence, that lymphatic drainage of the breast was separate from lymphatic drainage 
of the upper limb, as described by Sappey(11) and Turner -Warwick(12) and the 
hypothesis that lymph nodes draining the arm were not involved in patients with 
breast cancer. In the sentinel lymph node biopsy technique, the lymphatic channels 
and lymph node draining the breast are identified.  
Mapping the arm lymphatic channels and detection of arm draining lymph nodes and 
preserving them, may prevent lymphedema and the morbidity associated with it in 
patients undergoing axillary dissection, as anatomic continuity in arm lymphatic 
drainage is maintained. Potentially, this can save many more patients from the 
lymphedema complication than the sentinel node technique.  
However, there were reports of metastasis in ARM node and cross-over between the 
SLN and ARM node.(13) And according to oncological principles it is not safe to 
leave behind the metastatically involved arm draining nodes during ALND. 
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ARM technique  
It was first described using isosulphan blue dye by Suzanne Klimberg and team in  
Rockefeller Cancer Institute. After the induction of general anaesthesia, about 2-2.5 
ml of blue dye was injected subcutaneously or intradermally, in the upper inner aspect 
of the medial groove between the triceps and biceps muscles of the ipsilateral arm. 
This site was chosen as it is closer to axilla, which aided in quick drainage in the 
lymphatic channels and detection of lateral group of lymph nodes and also the skin 
tattoo at the site of the injection will be hidden underneath the clothing. The injection 
site was massaged and arm was elevated, to aid in drainage of the blue dye in the 
lymphatic channels towards axilla.(14)(15). The blue arm nodes were identified and 
dissected from the axilla and sent separately for histo-pathological evaluation 
The detection rates of blue arm lymphatic channels and arm nodes in patients 
undergoing axillary dissection, in various studies ranged from 40.6% to 91% 
(9)(10)(11)(16). Radioisotope (injected into the ipsilateral hand) was also used in 
combination with blue dye in increase the detection rates of arm node.(17) 
Complications such as pain, blue staining of skin and persistence of  staining for few 
months were reported, following ARM technique using blue dye.(18) 
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To increase detection rates and to reduce local complications caused by blue dye, 
radioisotopes and fluorescent dyes were used to trace the lymphatic channels. ARM 
technique, when performed using indocyanine green, a fluorescent dye and 
fluorescence imaging device, yielded 85% detection of arm lymphatic channels and 
arm node. (19) 
 
Preliminary work:  
Choosing between blue dye and fluorescence imaging techniques. 
 Lymphedema, secondary to axillary dissection is a major concern for most of our 
patients who are undergoing surgery for breast cancer. Incidence of lymphedema in 
patients undergoing the same procedure, is 25.24% at our institute. Axillary reverse 
mapping seems promising in preventing lymphedema in this group of patients. We 
wanted to assess the feasibility and safety of this technique, in our setting. 
 Initially we used methylene blue to map the arm lymphatic channels in few patients 
using the technique of intermuscular groove injection described earlier. But we were 
not able to detect the lymphatic channels or the arm node.  
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As the documented detection rates of arm lymphatic channels and arm lymph nodes 
using blue dye, in literature were low, we decided to use indocyanine green instead, 
which is a fluorescent dye to trace the lymphatic channels, after obtaining expert 
opinion from Dr. Suzanne Klimberg, Director of the Breast Cancer Program,  
Rockefeller Cancer Institute.  
Fluorescence imaging: 
Fluorescence imaging, is an efficient method of visualising cells, tissues and 
vasculature both invitro and invivo.(20) 
 Fluorescence imaging is superior to the current imaging modalities are that it has a 
good signal to noise ratio [SNR] making the area of interest visible in a dark 
background. It also has high sensitivity as lower concentrations of the fluorophore can 
be detected. And it provides good spatial and temporal information not only at 
molecular level but also of tissues and blood vessels and lymphatic channels. 
Near infrared fluorophores are probes whose excitation and emission wavelengths are 
in the range of 745-850nm. These fluorophores can be excited by an simple NIR 
LED/laser and emit a fluorescent signal with reduced scattering and have a good 
tissue penetration.(21) 
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The common fluorescent dyes used are ICG, Cy 5.5, Cy7, Irdye800 CW, and 
ProSense 750. At present, Indocyanine green dye is the o only NIR fluorophore 
approved by US Food and Drug Administration(FDA). 
Indocyanine green was first developed by Kodak research laboratories for NIR 
photography in 1955 and was approved for use in clinical applications in 1956(22) 
 
Properties of Indocyanine green dye: 
Its an anion, that belongs to the group of cyanine dyes. It‟s a tri-carbocyanine dye, 
with a molecular weight of 751.4Da. ICG in the dry form is stable at room 
temperature and it is available in this form in the pharmaceuticals. It is readily soluble 
in distilled water but not soluble in saline.(23) It is unstable in solutions (more than 10 
hours) at room temperature and when exposed to light.  It binds to the plasma 
lipoproteins and it does not alter the protein structures. It is does not have metabolites 
and it is excreted into the bile juice by the protein, glutathione S-transferase, in the 
liver.(24)  ICG is non toxic and non-ionising and its excitation and emission are 
within „tissue optical window‟ thus allowing the visualisation of deeper tissues.(25) 
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ICG binds with albumin on-specifically and produces singlet oxygen, which is binds 
to blood proteins. This makes ICG, non-toxic and also prevents its decomposition in 
the blood.(24) 
When ICG is bound with albumin, its excitation and emission occur at a higher 
wavelength.(26) 
Dosage of ICG: 
ICG was used on the basis of its dark green colour, at the dose of 25mg/dl for retinal 
and choroidal angiography.(27) It was administered at a dose of 0.5mg/kg to assess 
the hepatic function and 2 mg/kg to determine the cardiac output.(28)(29) 
Adverse effects of ICG: 
There were few reports of urticaria, nausea, dyspnea, peripheral vasodilation and 
severe anaphylaxis at the doses ranging from 0.5mg/kg to 5mg/kg.(30) 
 
Near infrared imaging:  
 NIR fluorescence imaging involves injection of a fluorophore(ICG), which is excited 
at wavelengths of 780 nm or greater, and has emission at  wavelengths of 800 nm or 
greater.  NIR fluorophores  can be repeatedly excited by the excitation light, and the 
time lapse between the excitation and emission is a nano-second.  
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Each molecule of fluorophore(ICG) can emit upto 100,000,000 photons per second, 
when compared to radionuclide, which gives only a single photon when it reaches to 
ground state. NIR fluorescence has higher tissue attenuation and scattering, which 
enhances good tissue penetration.(31) 
The NIR wavelength (>750nm) is the „tissue window‟ that is available for deep tissue 
imaging, without the interference of autoflourescence.  Autoflourescence is 
fluorescence emitted by endogenous fluorophores  such as NADPH and  flavin 
coenzymes in  lysosomes, mitochondria of the cells, and collagen and elastin in the 
extracellular matrix. This creates a background noise, which prevents detection of 
lower concentration of fluorophore in the tissues.  
In addition to this, there is leakage of excitation light, through the interference filters 
used to filter the backscattered excitation light and collect only the emitted signal. 
Thus the noise due to autofluorescence and excitation light leakage is higher than the 
emitted fluorescent signal from the fluorophore, which necessitates the use of higher 
sensitivity device and appropriate interference device and use of a higher amount of 
fluorophore, to collect afluorescent signal with a good resolution. (27) 
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Clinical applications of ICG and NIR imaging 
Intradermal route: 
ICG has been injected intra-dermal route, for the evaluation of lymphedema by Unno 
et al.(32) to assess dynamic lymphatic flow by Rasmussen(33)and for intraoperative 
assistance during lymphovenous anastamosis for the treatment of lymphedema by 
Ogata F et al.(34) 
Sevick-Muraca(35) determined the minimum dose of ICG, required for detecting 
sentinel lymph nodes in breast cancer. Murawa et al, demonstrated that ICG 
fluorescence has a higher sensitivity to detect sentinel lymph nodes over 
lymphoscintigraphy(36) 
Subcutaneous route: 
Kitai et al(37) demonstrated 94% detection rates of sentinel lymph node, using ICG 
and NIR imaging, in breast cancer(34).  ICG was used to detect sentinel lymph nodes 
in gastric cancer by Miyashiro et al(38), Tajima et al(39), lower rectal cancer by 
Noura et al(40), skin cancer by Tanaka et al(41), lung cancer by Ito et al(42), vulval 
cancer(43), prostate cancer(44).  ICG was also used to detect chylous fistulas 
intraoperatively by Kamiya et al(45). 
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Intravenous route: 
ICG fluorescence was used to detect patency of coronary grafts by Rubens et al(46), 
Taggart et al(47), Sekijima et al(48). It was also used to demonstrate hepatic blood 
flow and to visualise liver segments(49), and to identify lesions of hepatocellular 
carcinoma intraoperatively and to facilitate precise excision of the same(50).  
In Vascular surgery, ICG fluorescence was used to assess graft patency(51), visualise 
splanchnic circulation and diagnose peripheral arterial occlusive disease and critical 
limb ischemia(52). ICG due to its lipophilic properties can be used to localise 
atheromas and efficacy of foam sclerotherapy.(53) 
In neurosurgery, ICG fluorescence was found to be superior to conventional 
angiography to assess patency of vessels in micro-anastomosis in re-vascularisation 
bypass surgery, aneurysm remnants, stenosis or occlusions in the vessels(54). 
In reconstructive microsurgery, ICG was used to identify the perforators and assess 
the patency of microanastomosis. (51). It is also used to visualise the renal vasculature 
after kidney transplant(55) and also to assess muscle perfusion(56). 
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Choosing an appropriate NIR imaging device: 
In our background search, we found that, there were no near infrared imaging devices 
available for clinical use, in our country. The infrared imaging devices that are 
available in other countries such as Germany and Japan are very expensive and 
elaborate. Photodynamic Eye (PDE) Hamamatsu,  
SPY (Novadaq), 
 FDPM imager (Texas),  
IC-View (Pulsion Medical),  
FLARE (Israel Beth Deaconess Hospital),  
Custom system (Kochi Medical School) are the six investigational devices used in 
various published studies. These devices are elaborate and very expensive for the 
Indian setting. 
 The cost of the hand-held Photodynamic Eye device is approximately 23 lakh rupees 
(33,000 euros) 
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Developing an in-house NIR imaging system of low cost  
  Our next challenge was to devise an in-house, cost effective and a handy, near 
infrared imaging system, based on the principles of fluorescent imaging, for our study 
and also assess the feasibility of ARM technique using this technology in our study 
setting. 
 With the expertise at the Bio-engineering department in our institution we were able 
to devise a low cost, portable, near infrared imaging system using low end 
components that were available in the market. 
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Materials and methods 
Preliminary work: Choosing between blue dye and fluorescence imaging 
techniques. 
 Lymphedema, secondary to axillary dissection is a major concern for most of our 
patients who are undergoing surgery for breast cancer. Incidence of lymphedema in 
patients undergoing the same procedure, is 25.24% at our institute. Axillary reverse 
mapping seems promising in preventing lymphedema in this group of patients. We 
wanted to assess the feasibility and safety of this technique, in our setting. 
 Initially we used methylene blue to map the arm lymphatic channels in few patients 
using the technique of inter-muscular groove injection described earlier. But we were 
not able to detect the lymphatic channels or the arm node. As the documented 
detection rates of arm lymphatic channels and arm lymph nodes using blue dye, in 
literature were low, we decided to use indocyanine green instead, which is a 
fluorescent dye to trace the lymphatic channels, after obtaining expert opinion from 
Dr. Suzanne Klimberg, Director of the Breast Cancer Program,  Rockefeller Cancer 
Institute. 
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Methylene blue caused skin tattooing, pain and induration at the injection site, and 
the detection rates with methylene blue were reported to be only 61%.(57) 
Indocyanine green dye(ICG) was chosen above methylene blue as the identification 
rates of ARM  were  88% (58).  
Indocyanine green is a fluorescent dye. Its excitation and emission wavelengths are in 
between 765 nm - 800 nm and 810 nm - 850 nm respectively and it requires a near 
infrared imaging device to detect the fluorescent signal and to identify the lymphatic 
channels and lymph nodes in operating field. In our background search, we found that, 
there were no near infrared imaging devices available for clinical use, in our country. 
The infrared imaging devices that are available in other countries such as Germany 
and Japan are very expensive and elaborate.  
 Our next challenge was to devise an in-house, cost effective and a handy, near 
infrared imaging system, based on the principles of fluorescent imaging, for our study 
and also assess the feasibility of ARM technique using this technology in our study 
setting. 
At the Bio-engineering department in our institution we were able to devise a low 
cost, portable, near infrared imaging system using low end components that were 
available in the market.  
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ICG, when used alone, had a weak fluorescent signal in the tissues. It has a short half 
life and binds nonspecifically to lipoproteins in plasma and lymphatic channels (3). 
Using our prototype imaging system, we could not appreciate a fluorescent signal, 
when ICG was excited with 745 nm NIR light source, in our lab. In our further 
literature search, to find a solution the problem, we found that ICG when bound to 
albumin (Bovine serum albumin and 20% Human Serum albumin) had higher 
fluorescence intensity, compared to ICG alone. (4,5).  
 We had demonstrated this, using Bovine serum albumin (BSA) and Fluorescent 
imaging system [Camera System Info: Andor Newton; Camera Type: Andor, iKon; 
Camera CCD Type: DZ436) at Stem Cell Centre, Christian Medical College, Vellore.] 
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• ICG+ albumin  :        Excitation at 745nm;      
                                   Emission at 840 nm. 
ICG alone (left)                                                                       ICG+ BSA (right) 
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Fluorescence intensity map  
                             ICG alone                                                             ICG + BSA 
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The optimal ICG concentration for maximal fluorescence yield within the dermal 
layer was determined by dissolving various concentrations of ICG ranging from 0.1 to 
1 mg/ml in bovine serum albumin (BSA), with concentration of 60g/l. 
Bovine serum albumin is antigenic to the human body and causes systemic 
anaphylaxis. Human Serum albumin (HSA) is also known to cause anaphylactoid 
reactions and also severe anaphylaxis and there is a theoretical risk of transmission of 
viral diseases and there are no trials to prove its safety in humans.   
 
Innovating an ICG dye – patient serum combination to increase intensity of 
signal: 
We first explored the use of protein binding to increase signal intensity. However 
porcine derived albumin described in studies had the limitation of availability, cost 
and allergenecity. It seemed a natural solution to use the patient‟s own serum to 
combine with the ICG dye, Using this technique we found that the high signal 
intensity produced could be see very well with our low cost device thus setting the 
stage for the clinical study. 
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In-house Near infrared imaging system : 
In-house near infrared imaging system and optimal concentration of ICG and human 
serum (patent application is under review) 
 
Working examples 
ICG +albumin in a vial (fluorescence seen using the in-house NIR imaging system 
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Annual in-patient statistics of patients with breast disease in the Department of 
Endocrine Surgery, CMC Vellore, in the year 2013. 
 
 
 
Out of 432 in-patients with breast disorders, 343 patients (79%) had breast cancer. 
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Fig 2. Age distribution of patients with breast cancer treated as in-patients in the 
Department of Endocrine surgery, CMC Vellore in the year 2013 
 
Majority of patients with breast cancer belonged to the age group of 40-60 years. 
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Fig 3 TNM stage distribution of patients with breast cancer treated in the year 2013. 
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Fig 4. Types of surgeries performed for breast cancer based on the TNM staging of 
breast cancer in the Department of Endocrine Surgery, CMC Vellore. 
 
Total of 303 patients underwent modified radical mastectomy (simple mastectomy + 
axillary lymph node dissection) in Department of Endocrine Surgery  at CMC Vellore 
in the year 2013. 
Based on the above statistics, our sample size requirement to conduct our study was 
feasible. 
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Sample size calculation:  
Sample size: 
 Two Proportion - Hypothesis Testing - Large Proportion - Equal Allocation 
Proportion in group I    = .61 
Proportion in group II   = .88 
Risk difference               = -0.27 
Power(%)                        = 80 
Alpha Error(%)               = 5 
Side                                 = 2 
Required sample size for each arm = 40 
Alpha Error(%)            Power(%)            Sample Size(n) 
5                                       80                             40 
Note: with reference to (1) from  Thompson etal  (Blue dye) the detection rate was 
found to be (11/18 ie, 61% )and from Noguchi etal (2)it was (7/8 ie 88%) 
(Fluorescence ) with a power at 80% and alpha error at 5% for a 2 sided test we need 
to study 40 in each arm. 
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Statistical methods: 
All categorical variables will be analyzed using Chi-square test to find the association 
with ARM lymph node/lymphatic channel identified Y/N against the demographic 
variables. Continuous variables will be assessed using two independent sample T test. 
Frequency and Mean ± SD will be calculated as descriptive statistics. 
 
 
Inclusion criteria:   
1. Patients with breast cancer, undergoing axillary lymph node dissection,  
2. Clinically N1 stage breast cancer,  
3. Patients who underwent neo-adjuvant chemotherapy and hormonal therapy 
undergoing   axillary lymph node dissection,  
4. Post-lumpectomy status undergoing axillary lymph node dissection 
            breast conservation surgery with axillary lymph node dissection for early 
breast cancer. 
5. patients who have signed an informed consent form. 
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Exclusion criteria:   
1. Clinically proven N2 and N3 disease, 
2. Clinically proven T4a, T4b disease 
3. Patients suitable for sentinel lymph node biopsy, 
4. Patients who have received RT to axilla,  
5. Patients with metastatic breast disease( undergoing palliative mastectomy) 
 
Consort figure: 
              
 
 
 
 
 
52 patients  
Equal allocation  
Methylene blue arm
26 patients 
Indocyanine green (ICG) dye arm
26 patients
57 patients were enrolled 
52 patients were included 
(T1, T2,T3,N0, N1 clinical stage)
5 patients were excluded (T4, N2 
clinical stage)
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After standardising the technique of preparation of premixed solution of the ICG and 
patient‟s serum and the optimum amount of the dye that is required for injection and 
site of injection, we were able to detect the lymphatic channel and the lateral group of 
lymph nodes in 4 patients, who were recruited in the study based on inclusion criteria 
and after obtaining an informed consent. 
As this technique involved various steps in preparation of dye and setting up the 
imaging system before the operation, it was thought to be inefficient and labour 
intensive in our setting where there is a shortage of operating time and manpower.  In 
view of this, once the correct site of injection was identified, we returned to using 
methylene blue dye, which is readily available and could be injected at the same site, 
to detect the lymphatic channel and lateral group of lymph nodes. 
 
Site of the injection in ARM technique: 
Contrary to the usually described inter-muscular groove of the ipsilateral arm, we 
found that the region posterior to the proximal part of the inter-muscular groove was 
more accurate in mapping the arm lymphatics. Injection of the dye (both ICG and 
methylene blue) at this site increased our rates of identification of arm lymphatic 
channels and lateral group of lymph nodes. 
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Fig 6. Site of injection of the dye in ARM technique in patients with early breast 
cancer in Dept of Endocrine Surgery at CMC Vellore. 2014-2015 
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In our study we want determine and  compare the detection rates of the lymphatic 
channel and lymph node, using premixed solution ICG and patient serum with an in-
house imaging system and methylene blue dye and see whether it is feasible to use 
methylene blue, for mapping the arm lymphatic channel. 
 The use of blue dye injected in the site identified by ICG has now proved successful. 
The data of cases using both techniques can be analysed together for assessment of 
oncologic safety and separately for efficacy in the final analysis. 
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Results and Discussion: 
 
  
Fig 1. Age distribution of patients with early breast cancer in ARM study in the Dept. 
Endocrine Surgery  at CMC Vellore in 2014-2015. 
Majority of patients belonged to the age group of  40-60 years. 
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Fig 2.  Distribution of BMI of patients with early breast cancer in ARM study in the 
Dept. Endocrine Surgery,  at CMC Vellore in 2014-2015. 
 
 
 
 
 
 
 
33, 63%
13, 25%
6, 12%
BMI
normal 
overweight
obese
55 
 
 
 
 
Fig 3. T stage of patients with early breast cancer in ARM study in Dept of Endocrine 
Surgery, CMC Vellore in 2014-2015. 
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Fig 4. N stage of patients with early breast cancer in ARM study in Dept of Endocrine 
Surgery, CMC Vellore in 2014-2015. 
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Fig 5. TNM stage distribution of patients with early breast cancer in ARM study 
conducted in Dept of Endocrine Surgery, at CMC Vellore. 2014-2015 
Majority of patients with early breast cancer in the ARM study, belonged to stage IIB 
of TNM classification of breast cancer. 
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Fig 6. Histology of  tumour in patients with early breast cancer enrolled into ARM 
study in the Dept of Endocrine Surgery at CMC Vellore in 2014-2015. 
Ductal carcinoma is the most common type in patients with early breast cancer. 
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Fig 7. Distribution of patients with early breast cancer,  who received neoadjuvant 
treatment in ARM study in the Dept of Endocrine Surgery, at CMC Vellore.2014-
2015 
Only 27% of patients with early breast cancer received neoadjuvant chemotherapy. 
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Fig 8 Two types of dye were injected A. Indocyanine green B. Methylene Blue dye in 
equal proportion of patients with early breast cancer, in the ARM study at CMC 
Vellore 2014-2015. 
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Lymphatic channel and arm lymph node detected with methylene blue in patients with 
early breast cancer, in the ARM study at CMC Vellore 2014-2015. 
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Image showing lymphatic channel and draining lymphnode flowing dermal injection 
of premixed solution of patient’serum and ICG patients with early breast cancer, in 
the ARM study at CMC Vellore 2014-2015. 
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Fig 9. Identification rates of arm lymphatic channel and arm lymph node(lateral 
group) using indocyanine green and methylene blue in patients with early breast 
cancer in ARM study in Dept of Endocrine Surgery at CMC Vellore. 2014-2015. 
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Identification rates of lymphatic channel and lateral group of lymph node is 96.2% 
using indocyanine green (ICG) dye which is comparable to the identification rates 
reported in various studies using ICG alone and NIR imaging device. 
Identification rate of the lymphatic channel and lateral lymph node using methylene 
blue is 100% in our study, which is much higher than the reported rate in 
literature(61%). This is attributed to the identification of the correct site (posterior to 
the proximal part of the inter-muscular groove) for dye injection in ARM technique to 
visualise the arm lymphatics. 
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Fig 10. Metastatic rate in the ARM (lateral group) node in patients with early breast 
cancer in ARM study in Dept of Endocrine Surgery at CMC Vellore in 2014-2015. 
 
Metastatic rate in the  lateral group of lymph nodes  in our patients with early breast 
cancer was 5.8%.  
As the rate of metastasis in the arm node is low in patients with early breast cancer, 
once identified the arm  lymphatic channel and  lateral group of lymph nodes can be 
preserved, so as to prevent secondary lymphedema, following axillary dissection, thus 
making the ARM technique oncologically safe.  
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As the metastatic rate is low, adjuvant chemotherapy or radiotherapy  to axilla will be 
able to eradicate  any metastatic tumour deposits in lateral group of lymph nodes, 
when they are preserved. 
 
 
Fig 11.  Distance between the ARM node from the axillary vein, in patients with 
breast cancer, in ARM study conducted in Dept of Endocrine Surgery, in CMC 
Vellore. 2014-2015. 
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Fig 10 Location of ARM node, in patients with breast cancer in ARM study conducted 
in Dept of Endocrine Surgery, in CMC Vellore 2014-2015. 
 
The most common position of the lateral group of lymph node was 2 cm from the 
axillary vein and inferolateral to the thoracodorsal vessels in the axilla. 
 
 
 
 
49
1
1
0 10 20 30 40 50 60
Inferolateral
Inferomedial
Superomedial
68 
 
 
 
Fig. 10. Rate of complications following injection of methylene blue and Indocyanine 
green dye in patients with early breast cancer in ARM Study conducted in Dept of 
Endocrine Surgery at CMC Vellore 2014-2015. 
 
57.7% of patients who were in the methylene blue group developed pain, induration 
and skin tattooing who were on follow up in OPD for 6-8 days post surgery. 
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During our study, as we noticed that patients who received methylene blue for reverse 
mapping, developed pain, induration and skin discolouration. To decrease this 
morbidity, we further reduced the amount of methylene blue to 2ml and massaged the 
site of injection longer, with raising the arm to facilitate drainage of the dye into the 
arm lymphatic channels. 
Despite these efforts, the local complications following methylene blue injection were 
still persistent. This is probably due to the viscosity of methylene blue which does not 
allow it to  readily dissolve in the lymph and may clog the lymphatic channels, 
disrupting the normal flow of lymph in the arm lymphatic channels, causing local 
swelling and induration of the arm. 
Methylene dye probably could not drain because we were removing the draining 
lymphatics and nodes in the lateral group to assess the safety of the procedure. In a 
further study we will need to define the complication rate when the procedure is 
performed therapeutically and the lymphatics and nodes are preserved which may 
allow adequate drainage and reduce retention of the dye in the skin. 
Amongst these patients, one patient on her follow up for adjuvant chemotherapy 
complained of persistent swelling at the site of injection. On examination she was 
found to have induration at that site without any tenderness or skin tattooing. 
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Limitations  
 
The estimated sample size for our study could be met as some patients refused to 
consent for the procedure and logistic issues. Only 52 patients could be enrolled into 
the study and they were equally allocated to the methylene blue group and 
indocyanine green group with 26 patients in each.  
Conclusions 
 
1. Identification rate of arm lymphatics and lateral group of lymph node using 
indocyanine green dye were 96.2%, which is comparable to the reported 
identification rate in various studies. 
 
2. There were no complications following the injection of ICG. None of the 
patients had any pain, swelling or skin tattooing at the site of the injection. 
 
 
3. Identification rate of lymphatic channel and lateral group of lymph node using 
methylene blue were 100%, following the identification of the accurate site of 
injection of the dye in ARM technique. 
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4. Though the identification rates were high with methylene blue, 57.7%  of 
patients developed  local complications following methylene blue, which 
increased the post-operative morbidity. 
 
5. Metastatic rate in the lateral group of lymph nodes in patients with early breast 
cancer  is only 5.8%..  This low rate of metastasis , early breast cancer, could 
be treated with adjuvant chemotherapy or radiotherapy, which is already 
planned as a the course of treatment in  these patients. This may allow the 
lateral group of lymph nodes to be preserved  in axillary lymph node 
dissection,  to prevent secondary  lymphedema of the ipsilateral arm. 
 
6. Axillary reverse mapping technique is not only feasible but it can also be 
oncologically safe in patients with early breast cancer. 
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Anexures 
Consent form 
 
Christian Medical College, Vellore 
Department of Endocrine Surgery 
Research project :     Axillary Reverse Mapping in breast cancer [ARM study} 
using premixed solution of  Indocyanine green[ICG] dye and autologous serum,  
and an in-house near infrared imaging system. 
Consent form 
Patient name:                                                   Age :         Sex:          Hospital number:                                                                                                      
Name of the operation:                                                                                 Date :      
 
Patient  
I voluntarily agree to take part in this study. 
The doctor named in this form has explained the benefits and risks of the proposed 
procedure to me. 
I agree to the proposed procedure. 
I declare that I have read the information sheet provided to me regarding this study 
and have clarified any doubts that I have had. 
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I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting 
my usual treatment or my legal rights. 
 I understand that I will not receive any other financial compensation. 
  I understand that my identity will not be relieved in any information released to third 
parties or published. 
I agree to clinical photographs being taken during the course of my stay in hospital. I 
know that my identity will be protected and that this will be used only for educational 
purposes. 
I know that there will be no intervention done in the treatment of my condition based 
on the findings; however this study may benefit the patients who are undergoing 
similar surgery for breast cancer, in future. 
 
Signature of the patient:      
Name of the patient:                                                                                       Date:         
Witness: 1. ____________   (signature)                    1.______________ (Name in 
block letters) 
Witness: 2. _____________(signature)                     2.______________(Name in 
block letters) 
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With regard to the procedure: 
    I confirm that I have explained the indications, benefits and common risks. I have 
done this in terms and language which in my judgment are suited to the understanding 
of the patient. 
Name of the doctor: 
Signature with Emp no:                                                                         Date: 
 
Contact details of principal investigator: 
Dr. Jyothsna. M, 
PG Registrar, 
Dept. of General Surgery, 
CMC Vellore – 632 004. 
Mobile number: 08220313955. 
Email id: jyoths03@gmail.com                                                                                                                                     
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Christian Medical College, Vellore 
Department of Endocrine Surgery 
Research project :   Axillary Reverse Mapping in breast cancer [ARM study} using 
Methylene blue dye. 
Consent form 
Patient name:                                                   Age :         Sex:                    Hospital number:                                                                                                      
 
Name of the operation:                                                                                 Date :      
 
 
Patient 
I voluntarily agree to take part in this study. 
The doctor named in this form has explained the benefits and risks of the proposed procedure 
to me. 
I agree to the proposed procedure. 
I declare that I have read the information sheet provided to me regarding this study and have 
clarified any doubts that I have had. 
I also understand that my participation in this study is entirely voluntary and that I am free to 
withdraw permission to continue to participate at any time without affecting my usual 
treatment or my legal rights. 
 I understand that I will not receive any other financial compensation. 
  I understand that my identity will not be relieved in any information released to third parties 
or published. 
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I agree to clinical photographs being taken during the course of my stay in hospital. I know 
that my identity will be protected and that this will be used only for educational purposes. 
I know that there will be no intervention done in the treatment of my condition based on the 
findings; however this study may benefit the patients who are undergoing similar surgery for 
breast cancer, in future. 
 
Signature of the patient:      
Name of the patient:                                                                                       Date:          
 
Witness: 1. ____________   (signature)                    1.______________ (Name in block 
letters) 
Witness: 2. _____________(signature)                     2.______________(Name in block 
letters) 
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With regard to the procedure: 
    I confirm that I have explained the indications, benefits and common risks. I have done this 
in terms and language which in my judgment are suited to the understanding of the patient. 
Name of the doctor: 
Signature with Emp no:                                                                         Date: 
 
Contact details of principal investigator: 
Dr. Jyothsna. M, 
PG Registrar, 
Dept. of General Surgery, 
CMC Vellore – 632 004. 
Mobile number: 08220313955. 
Email id: jyoths03@gmail.com                                                                                                                                     
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Proforma                                             
                                           DEPARTMENT OF ENDOCRINE SURGERY                    Date : ______ 
                                             CHRISTIAN MEDICAL COLLEGE, VELLORE 
  RESEARCH PROJECT   :  AXILLARY REVERSE MAPPING IN BREAST CANCER [ARM 
study] 
 Patient  Name :                            Hospital Number:              Age  :                         
 Weight : _____ Kg                  Height  :_____cms                    BMI :____Kg/m2 
 Diagnosis :  
 Clinical T  Classification :  Tx/T1/ T2 / T3/ T4      Size Of The Tumour: ____cm 
 Clinical N Classification :  N0 /N1/  N2 / N3  Supraclavicular Node:  present/absent 
 Clinical Stage :    I     IIa       IIb       IIIa        IIIb      IIIc            
 Method of Diagnosis of Primary Tumor : FNAC : Y/N;  Core Needle Biopsy: Y/N;  
Excision: Y/N             Distant metastasis at diagnosis:  present/ absent  
 Histology:  1.Ductal  not specified  
                   2. Ductal special type- medullary/colloid/tubular         3. Lobular                       
                    ER:  Positive/ Negative     Her-2/Neu    :  Positive/Negative 
 Neo-adjuvant Treatment :  Chemotherapy/Hormonal/Radiotherapy to axilla/none 
 Name of the Surgery:_______________                    Date of Surgery :____________ 
 Arm Procedure : 
 Time of Injection :                                 Time Of Axillary Exposure : 
 Time Interval : _________ mins 
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Location of the ARM node and lymphatic channel 
  Lymphatics identified :    yes/no                   -number  identified  : ___ 
 ARM  lymph node identified : yes/no            -number identified : ____ 
 Distance between the axillary vein to the ARM node :   ______cm 
 Location of the ARM  node in relation to the thoraco-dorsal bundle: 
 Inferolateral /  superolateral/inferomedial / superomedial 
 Post procedure: pain at the site : yes/ no Local reaction:  yes/no       duration : 
______ 
 Any other complaints : ________________________ 
 Metastasis in  ARM node : present/absent          Ajcc  classification:__________ 
 Post chemotherapy changes in ARM node  : present/absent 
 Histotype and grade of the tumor: ________________________ 
 Peritumoral lymphovascular invasion : present/absent 
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TNM Staging of carcinoma breast 
. TNM Staging System for Breast Cancer  
Primary tumor (T)   
TX  Primary tumor cannot be assessed  
T0  No evidence of primary tumor  
Tis Carcinoma in situ  
Tis (DCIS) : Ductal carcinoma in situ  
Tis (LCIS) : Lobular carcinoma in situ  
Tis (Paget)  
Paget’s disease of the nipple with no tumor  
Note: Paget’s disease associated with a tumor is classified according to the size of the tumor.  
T1  
Tumor 2 cm in greatest dimension  
T1mic  Microinvasion 0.1 cm in greatest dimension  
T1a  Tumor 0.1 cm but not 0.5 cm in greatest dimension  
T1b  Tumor 0.5 cm but not 1 cm in greatest dimension  
T1c Tumor 1 cm but not 2 cm in greatest dimension  
T2 Tumor 2 cm but not 5 cm in greatest dimension  
T3  Tumor 5 cm in greatest dimension  
T4  Tumor of any size with direct extension to  
(a) chest wall or  
(b) skin, only as described below  
T4a  Extension to chest wall, not including pectoralis muscle  
T4b  Edema (including peau d’orange) or ulceration of the skin of the breast, or satellite skin nodules confined to the  
same breast  
T4c Both T4a and T4b  
T4d  Inflammatory carcinoma  
 
 
 
 
 
 
 
 
 
 
 
 
 
Regional lymph nodes (N)  
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NX  Regional lymph nodes cannot be assessed (eg, previously removed)  
N0  No regional lymph node metastasis  
N1 Metastasis in movable ipsilateral axillary lymph node(s)  
N2 Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent* ipsilateral internal  
mammary nodes in the absence of clinically evident axillary lymph node metastasis  
N2a  Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) or to other structures  
N2b  Metastasis only in clinically apparent* ipsilateral internal mammary nodes and in the absence of clinically  
evident axillary lymph node metastasis  
N3  Metastasis in ipsilateral infraclavicular lymph node(s), or in clinically apparent* ipsilateral internal mammary  
lymph node(s) and in the presence of clinically evident axillary lymph node metastasis; or metastasis in  
ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node  
involvement  
N3a  Metastasis in ipsilateral infraclavicular lymph node(s) and axillary lymph node(s)  
N3b  Metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)  
N3c Metastasis in ipsilateral supraclavicular lymph node(s)  
 
Regional lymph nodes (pN)†  
pNX  Regional lymph nodes cannot be assessed (eg, previously removed or not removed for pathologic study)  
pN0  No regional lymph node metastasis histologically, no additional examination for isolated tumor cells‡  
pN0(i) No regional lymph node metastasis histologically, negative IHC  
pN0(i)  No regional lymph node metastasis histologically, positive IHC, no IHC cluster 0.2 mm  
pN0(mol) No regional lymph node metastasis histologically, negative molecular findings (RT-PCR)  
pN0(mol) No regional lymph node metastasis histologically, positive molecular findings (RT-PCR)  
pN1mi  Micrometastasis (0.2 mm, none 2.0 mm)  
pN1  Metastasis in one to three axillary lymph nodes and/or in internal mammary nodes with microscopic disease  
detected by sentinel lymph node dissection but not clinically apparent§  
pN1a  Metastasis in one to three axillary lymph nodes  
pN1b  Metastasis in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but  
not clinically apparent§  
pN1c Metastasis in one to three axillary lymph nodes and in internal mammary lymph nodes with microscopic  
disease detected by sentinel lymph node dissection but not clinically apparent§, 
 pN2  Metastasis in four to nine axillary lymph nodes, or in clinically apparent* internal mammary lymph nodes in the  
absence of axillary lymph node metastasis  
pN2a  Metastasis in four to nine axillary lymph nodes (at least one tumor deposit 2.0 mm)  
pN2b Metastasis in clinically apparent* internal mammary lymph nodes in the absence of axillary lymph node  
metastasis  
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TNM Stage Grouping for Breast Cancer  
Stage 0  
Tis N0 M0  
Stage I  
T1* N0 M0  
Stage IIA  
T0 N1 M0  
T1* N1 M0  
T2 N0 M0  
Stage IIB  
T2 N1 M0  
T3 N0 M0  
Stage IIIA  
T0 N2 M0  
T1* N2 M0  
T2 N2 M0  
T3 N1 M0 - 
T3 N2 M0  
Stage IIIB  
T4 N0 M0  
T4 N1 M0  
T4  N2 M0  
Stage IIIC    
Any T N3 M0  
Stage IV    
Any T  Any N  M1  
 
 
 
 
 
 
